ReviewFrontiers in oncology2025
Downregulation of PAQR3 expression predicts poor prognosis of patients with pan-cancer: a meta-analysis.
Review in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The role of PAQR3 in cancer progression - Molecular regulation, signaling pathways, and clinical implications: A review.Biomolecules & biomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to evaluate the association between progestin and adipoQ receptor 3 (PAQR3) expression and survival outcomes, as well as disease progression, through a meta-analysis. A systematic literature search was conducted across multiple academic databases, including Cochrane Library, Embase, PubMed, Web of Science, and Google Scholar. Relevant studies were identified and screened based on predefined inclusion and exclusion criteria. Statistical analyses, including odds ratios (ORs), hazard ratios (HRs), and 95% confidence intervals (CIs), were employed to assess the relationship between PAQR3 expression levels and prognostic outcomes, as well as clinicopathological features in pan-cancer patients. A total of 1032 patients from nine eligible studies were included in the meta-analysis. The results demonstrated that high PAQR3 expression was significantly associated with improved overall survival (HR = 0.32; 95% CI = 0.19-0.56) and disease-free survival (HR = 0.35; 95% CI = 0.20-0.61) in pan-cancer patients. Downregulation of PAQR3 expression was significantly correlated with adverse clinicopathological characteristics, including lymph node metastasis (HR = 0.22; 95% CI = 0.06-0.82), higher histological grade (HR = 0.31; 95% CI = 0.12-0.81), advanced pathological stage (HR = 0.18; 95% CI = 0.05-0.66), tumor size (HR = 0.73; 95% CI = 0.36-1.5), distant metastasis (HR = 0.36; 95% CI = 0.07-1.82), and tumor invasion (HR = 0.18; 95% CI = 0.11-0.29). However, no significant associations were observed between PAQR3 expression and gender (HR = 0.94; 95% CI = 0.59-1.5) or age (HR = 1.10; 95% CI = 0.77-1.56). In conclusion, reduced PAQR3 expression in pan-cancer patients is associated with worse clinical outcomes and may promote cancer progression. These findings suggest that PAQR3 could serve as a potential prognostic biomarker and therapeutic target for cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.